Stock listing

Frankfurt:5GH Guardant Health, Inc. Aktie

German listing (Frankfurt) of Guardant Health, Inc. · home listing NASDAQ:GH

Follow Guardant Health, Inc. into a list and get an email when it puts out news.

Share price · FWB:5GH

€159.42 EUR +6.98 (+4.6%)

Close on Oct 30, 2026

Day range
€159.42 – €160.58 EUROct 30, 2026
Market cap
€21.39B EURAt the close on Oct 30, 2026 · price × 134.2M shares outstanding
Guardant Health, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:GH · Home$170.73 USD-8.07 (-4.5%)2,389,042$179.50$180.05$167.94$178.80Close on Nov 2, 2026
Frankfurt:5GH€159.42 EUR+6.98 (+4.6%)—€160.58€160.58€159.42€152.44Close on Oct 30, 2026
Ticker
Frankfurt:5GH
Asset type
Stock
Sector
Health care
Industry
Diagnostics & research services
Exchange
Frankfurt
Currency
EUR

What changed lately

Calls

Upcoming

  • Guardant Health (NASDAQ:GH) Q3 2026 Earnings Call

    Thu, Nov 05, 2026 · 4:30 PM ET

    Register

Replays

  • Guardant Health (NASDAQ:GH) Q2 2026 Earnings Call

    Thu, Jul 30, 2026 · 4:30 PM ET

    Watch Transcript

  • Guardant Health (NASDAQ:GH) Q1 2026 Earnings Call

    Thu, May 07, 2026 · 4:30 PM ET

    Watch Transcript

  • Guardant Health (NASDAQ:GH) Q3 2025 Earnings Call

    Wed, Oct 29, 2025 · 4:30 PM ET

    Watch Transcript

Latest news

Guardant Health Wins 2026 Prix Galien USA Award for Best Medical Technology for Shield Blood Test

Nov 3, 2026

Guardant Health Applauds New Law Ensuring Access to Colorectal Cancer Screening Innovations with No Cost-Sharing for Pennsylvanians

Oct 29, 2026

Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 2026

Oct 20, 2026

Guardant Health Shield Blood Test Demonstrates Leading Screening Adherence and CRC Deaths Averted Compared to Stool-Based Tests

Oct 15, 2026

Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer

Oct 8, 2026

Guardant Health to Report Third Quarter 2026 Financial Results on November 5, 2026

Oct 8, 2026

Guardant Health COSMOS Study Published in Cancer Research Communications Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Melanoma

Oct 5, 2026

Guardant Health’s Shield Blood Test Covered by EviCore by Evernorth for Colorectal Cancer Screening

Sep 14, 2026

Guardant Health and Collaborators to Present 20 Abstracts Highlighting Portfolio of Liquid Biopsy Tests for Early Detection and Ongoing Treatment Management at 2026 World Conference on Lung Cancer

Sep 9, 2026

Business Insider Names Guardant Health One of America's Most Innovative Businesses

Sep 8, 2026

All Guardant Health, Inc. news

Decks

Guardant Health, Inc. on 6ix

Sector
Health care
Industry
Diagnostics & research services
News releases
61 in the last 12 months · 290 in all · newest Nov 3, 2026 · oldest 2019
Calls
20 calls with a replay · 20 with a transcript · latest Jul 30, 2026
Decks
47 decks · latest Jul 30, 2026

Where Guardant Health, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:GH · Home listingNASDAQUnited StatesUSD
gettex:5GHgettexGermanyEUR
LS Exchange:A2N5RYLS ExchangeGermanyEUR
Lang & Schwarz:A2N5RYLang & SchwarzGermanyEUR
Tradegate:5GHTradegateGermanyEUR
BX Swiss:GHBX SwissSwitzerlandCHF
BMV:GHBMVMexicoMXN
BIVA:GHBIVAMexicoMXN
BOATS:GHBOATSUnited StatesUSD
Milan:1GHMilanItalyEUR
Frankfurt:5GH · This pageFrankfurtGermanyEUR
Munich:5GHMunichGermanyEUR
Dusseldorf:5GHDusseldorfGermanyEUR
Hamburg:5GHHamburgGermanyEUR
Stuttgart:5GHStuttgartGermanyEUR
Hanover:5GHHanoverGermanyEUR
Xetra:5GHXetraGermanyEUR

Log in to ask 6ix AI your own questions about Guardant Health, Inc.